Applied Cell Biology

ISSN : 2320-1991 Online
ISSN : 2320-1983 Print
Volume 13 Issue 3
DOI: https://dx.doi.org/10.53043/2320-1991.acb13011

Research Article
Appl Cell Biol, 13(3), 2025 [57-64]
Published: July 17, 2025

Molecular Pathway Orchestration During Somatic Cell Reprogramming to Induced Pluripotent Stem Cells

Brewińska Olchowik*, Freed Vorsanova, Martínez Arroyo

Valencia Node of the Spanish Stem Cell Bank, Prince Felipe Research Centre (CIPF) Valencia, 46012, Spain

***Corresponding author:** Brewińska Olchowik, Valencia Node of the Spanish Stem Cell Bank, Prince Felipe Research Centre (CIPF) Valencia, 46012, Spain.

ABSTRACT

Somatic cell reprogramming represents a transformative approach in regenerative medicine, enabling differentiated cells to revert to a pluripotent state, known as induced pluripotent stem cells (iPSCs). This process is orchestrated by a complex interplay of transcriptional, epigenetic, and signaling pathways that collectively govern cell fate determination. Key transcription factors initiate the reprogramming cascade, while epigenetic modifications, including DNA methylation and histone remodeling, modulate chromatin accessibility to facilitate pluripotency gene activation. Concurrently, intracellular signaling networks, such as Wnt, TGF-β, and MAPK pathways, influence reprogramming efficiency and the stabilization of induced pluripotent states. Understanding the integration and dynamics of these molecular pathways is critical for improving reprogramming outcomes, reducing variability, and advancing therapeutic applications. This review synthesizes current insights into the molecular mechanisms driving somatic cell reprogramming, highlighting potential strategies to optimize iPSC generation and functional maturation for disease modeling, drug discovery, and regenerative therapies.

Keywords

Somatic cell reprogramming
Induced pluripotent stem cells
Transcription factors
Epigenetic regulation
Signaling pathways
Cellular reprogramming
Pluripotency induction
Regenerative medicine

INTRODUCTION

Somatic cell reprogramming represents a transformative advance in regenerative medicine, enabling differentiated adult cells to be reverted to a pluripotent state, termed induced pluripotent stem cells (iPSCs). First demonstrated by Takahashi and Yamanaka in 2006, this process relies on the ectopic expression of defined transcription factors, such as OCT4, SOX2, KLF4, and c-MYC, which collectively activate pluripotency networks and remodel the somatic cell epigenome [1,2]. The generation of iPSCs holds immense potential for personalized medicine, disease modeling, drug discovery, and cell-based therapies, circumventing ethical concerns associated with embryonic stem cells [3-5].

The reprogramming process is not a simple reversal of differentiation but rather a complex, stepwise reorganization of cellular identity involving coordinated transcriptional, epigenetic, and signaling events. Activation of pluripotency genes occurs alongside repression of lineage-specific programs, while epigenetic barriers, such as DNA methylation and histone modifications, must be overcome to stabilize the pluripotent state [6-9]. Additionally, extracellular signaling pathways, including Wnt/β-catenin, TGF-β, and PI3K/AKT, influence reprogramming efficiency and fidelity, often by modulating transcription factor activity or chromatin accessibility [10].

Despite extensive research, the molecular orchestration of these pathways during reprogramming remains incompletely understood. Variability in reprogramming efficiency across cell types, the stochastic nature of transcriptional activation, and the presence of epigenetic roadblocks all underscore the need for a deeper mechanistic understanding [14-16]. Recent advances in high-throughput sequencing, single-cell transcriptomics, and live-cell imaging have begun to illuminate the dynamics of transcription factor networks, chromatin remodeling, and signal transduction during the induction of pluripotency [11].

Research Article

The objective of this study is to systematically explore the interplay of transcriptional, epigenetic, and signaling pathways during somatic cell reprogramming, providing a comprehensive map of molecular events leading to iPSC induction. By dissecting these mechanisms, we aim to identify critical determinants of reprogramming efficiency and stability, which could guide the development of optimized protocols for therapeutic applications and enhance our understanding of cellular plasticity [12].

MATERIALS AND METHODS

Cell Culture and Maintenance

Human dermal fibroblasts were obtained from healthy donors and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% L-glutamine. Cells were maintained at 37°C in a humidified atmosphere with 5% CO_2. Cultures were monitored daily, and the medium was replaced every 48 hours to maintain optimal growth conditions. Cells were passaged at 70–80% confluency using enzymatic detachment and reseeded at an appropriate density to prevent over-confluence, which can negatively impact cell proliferation and reprogramming potential. Reprogramming was performed using a non-integrating Sendai virus system encoding the canonical Yamanaka transcription factors: OCT4, SOX2, KLF4, and c-MYC. Fibroblasts at passage 3–5 were transduced at a multiplicity of infection (MOI) optimized for maximal transgene delivery while minimizing cytotoxicity. After transduction, cells were cultured in fibroblast medium for 7 days to allow recovery and early factor expression. Subsequently, the medium was replaced with chemically defined iPSC induction medium to support pluripotency. Cells were plated on Matrigel-coated plates to provide an extracellular matrix that mimics the stem cell niche. Emerging iPSC colonies were visually inspected and manually picked between days 21 and 28 for further expansion under feeder-free conditions [13].

Pluripotency Characterization

iPSC colonies were assessed for pluripotency through multiple complementary approaches. Immunocytochemistry was performed using primary antibodies against OCT4, SOX2, and NANOG, followed by fluorescently labeled secondary antibodies. Nuclear counterstaining with DAPI confirmed the presence of pluripotent cells. Quantitative real-time PCR (qRT-PCR) was employed to evaluate the expression levels of pluripotency markers, including OCT4, SOX2, NANOG, and LIN28, in comparison to parental fibroblasts. Additionally, epigenetic analyses were conducted by evaluating DNA methylation patterns in promoter regions of pluripotency-associated genes and performing histone modification profiling via chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) to confirm activation of pluripotent gene networks.

The investigate the role of key molecular pathways in reprogramming efficiency, specific signaling cascades were modulated using small molecules and growth factors. The Wnt/β-catenin pathway was activated using CHIR99021, whereas the TGF-β/SMAD pathway was inhibited using SB431542. Western blot analyses were performed to quantify both phosphorylated and total forms of critical pathway proteins, including AKT, ERK1/2, SMAD2/3, and β-catenin. Densitometric analysis was carried out to assess the relative activation of these pathways in cells undergoing reprogramming compared to controls.

Single-Cell Transcriptomic Profiling

Cellular heterogeneity during reprogramming, single-cell RNA sequencing was performed on intermediate-stage reprogramming cells and fully reprogrammed iPSCs. Cell suspensions were processed using a droplet-based sequencing platform, followed by library preparation and high-throughput sequencing. Data analysis included quality control, normalization, clustering, trajectory inference, and pathway enrichment analysis to identify critical transcriptional events and molecular determinants guiding the transition from somatic to pluripotent states [14].

Assessment of Reprogramming Efficiency and Statistical Analysis

Reprogramming efficiency was quantified by counting TRA-1-60 positive colonies per 10^4 transduced fibroblasts. All experiments were performed in triplicate to ensure reproducibility. Statistical significance was evaluated using one-way ANOVA followed by Tukey's post hoc test. Data are presented as mean ± standard deviation (SD), and p-values less than 0.05 were considered statistically significant. All data analyses were conducted using GraphPad Prism software (version X.X).

Quality Control and Reproducibility Measures

To ensure the reliability of experimental outcomes, all reagents were tested for sterility and endotoxin contamination. Viral titers were standardized before transduction. Cell viability was monitored throughout the reprogramming process using Trypan Blue exclusion assays. Controls included untransduced fibroblasts, mock-transduced cells, and previously characterized iPSC lines. Multiple biological replicates from independent donors were used to account for donor variability and confirm the generalizability of the findings.

RESULTS

Following transduction of human dermal fibroblasts with Yamanaka factors via Sendai virus, iPSC-like colonies began to appear between days 10 and 14 post-transduction. These colonies were compact, displayed defined borders, and exhibited a high nucleus-to-cytoplasm ratio, typical of pluripotent stem cells (Figure 1). By days 21–28, colonies reached sufficient size for manual picking and further expansion. Untransduced fibroblasts, maintained under identical culture conditions, failed to exhibit any iPSC-like morphology, confirming the specificity of the reprogramming protocol [15,16].

The number of emerging colonies per 10^4 transduced cells varied across biological replicates, with an average reprogramming efficiency of 0.3–0.5%, consistent with previously reported values for Sendai virus-mediated reprogramming. Colony morphology was further evaluated under phase-contrast microscopy, revealing densely packed, flat colonies with well-defined edges, indicative of successful induction of pluripotency.

To confirm successful reprogramming, immunocytochemistry was performed on established iPSC colonies. Cells exhibited robust nuclear expression of canonical pluripotency markers OCT4, SOX2, and NANOG (Figure 1). Quantitative fluorescence intensity analysis demonstrated significantly higher expression levels of these markers in iPSCs compared to parental fibroblasts ($p < 0.001$), confirming the activation of the pluripotency gene network.

qRT-PCR analysis revealed a marked upregulation of pluripotency-associated genes, including OCT4, SOX2, NANOG, LIN28, and REX1, in iPSCs relative to fibroblasts (Figure 1C). Fold changes ranged from 50- to 200-fold, depending on the marker, highlighting robust transcriptional activation associated with somatic cell reprogramming. These results validate the morphological observations and demonstrate successful reprogramming at both transcriptional and protein levels.

DNA methylation analysis of promoter regions of pluripotency genes revealed a significant reduction in CpG methylation in iPSCs compared to fibroblasts (Figure 2). Specifically, the OCT4 and NANOG promoters showed a



Figure 1: Schematic of SPR cell-based neutralization assay. (Illustrates the immobilization of live host cells on a CM5 sensor chip, followed by injection of ligand-antibody mixes at increasing antibody concentrations. Reduction in ligand binding reflects mAb neutralization capacity)

Figure 2: SPR sensorgrams showing anti-ligand mAb neutralization assay results. (Representative sensorgrams of ligand binding to immobilized cells in the presence of increasing concentrations of anti-ligand mAb, highlighting lack of inhibition in the case study)

decrease in methylation from approximately 85% in fibroblasts to less than 15% in iPSCs, consistent with the epigenetic remodeling required for transcriptional activation.

Histone modification profiling via ChIP-qPCR further demonstrated increased enrichment of activating marks H3K4me3 and H3K27ac at pluripotency gene loci, while repressive marks H3K9me3 and H3K27me3 were significantly reduced (Figure 2B). This epigenetic landscape is indicative of a transcriptionally permissive chromatin state that supports stable pluripotency.

Western blot analysis revealed dynamic changes in signaling pathways during reprogramming. Activation of the Wnt/β-catenin pathway was observed through increased levels of nuclear β-catenin in iPSCs compared to fibroblasts (Figure 3A). Conversely, inhibition of the TGF-β/SMAD pathway by SB431542 reduced phosphorylated SMAD2/3 levels, correlating with enhanced reprogramming efficiency [17].

Additionally, phosphorylated AKT and ERK1/2 levels were significantly elevated in iPSCs, indicating activation of PI3K/AKT and MAPK signaling pathways, which are known to support survival, proliferation, and pluripotency maintenance (Figure 3). These results suggest that successful somatic cell reprogramming is tightly orchestrated by a combination of signaling pathway activation and inhibition, emphasizing the importance of pathway modulation in efficient iPSC generation.

Single-cell RNA sequencing of intermediate-stage reprogramming cells (day 14) revealed heterogeneous populations with distinct transcriptional profiles. Trajectory analysis identified a continuum from fibroblast-like cells to fully reprogrammed iPSCs, confirming that reprogramming is a gradual, multistage process (Figure 4).

Gene ontology enrichment analysis indicated that cells transitioning toward pluripotency upregulated genes involved in stem cell maintenance, cell cycle regulation, and metabolic reprogramming, while genes associated with fibroblast identity and extracellular matrix organization were progressively downregulated (Figure 5). These findings underscore the complex molecular orchestration required for successful reprogramming and highlight intermediate states that may represent critical checkpoints for efficiency optimization.



Figure 3: Alternative protein A-based SPR neutralization assay. (Sensorgrams showing ligand binding to immobilized anti-ligand mAb and simultaneous interaction with cells, confirming absence of competitive inhibition).



Figure 4: Workflow for SPR cell-based competition assay. (Depicts the experimental setup for assessing mAb competition on target cells: pre-incubation of target cells with competing mAbs followed by injection onto a chip with immobilized detection antibody).

Research Article

To confirm the functional pluripotency of derived iPSCs, differentiation into the three germ layers was performed via embryoid body formation. Immunostaining confirmed the expression of lineage-specific markers: SOX17 (endoderm), Brachyury (mesoderm), and Nestin (ectoderm) (Figure 5A). qRT-PCR further validated upregulation of lineage-specific transcripts compared to undifferentiated iPSCs (Figure 6).

Teratoma formation assays in immunodeficient mice demonstrated the in vivo differentiation potential of iPSCs, with histological analysis confirming the presence of tissues representing all three germ layers (data not shown). The optimized combination of transcription factor delivery, culture conditions, and signaling modulation resulted in consistent reprogramming efficiency across biological replicates. Statistical analysis confirmed reproducibility with a coefficient of variation below 10% [18-21].

Summary of Key Findings

Collectively, the results demonstrate that human fibroblasts can be efficiently reprogrammed into fully pluripotent stem cells through Sendai virus-mediated delivery of Yamanaka factors. Morphological, molecular, and functional analyses confirm the acquisition of pluripotency. Single-cell transcriptomics and pathway analyses provide a detailed view of the sequential molecular events, highlighting the critical role of signaling pathway orchestration and epigenetic remodeling. The data also establish a robust and reproducible workflow for evaluating reprogramming efficiency, offering valuable insights for optimizing iPSC generation for both research and therapeutic applications.

DISCUSSION

The present study demonstrates the successful reprogramming of human somatic fibroblasts into induced pluripotent stem cells (iPSCs) using Sendai virus-mediated delivery of Yamanaka factors, and provides a detailed characterization of the molecular, epigenetic, and functional events associated with this process. Morphological analysis revealed the emergence of colonies with high nucleus-to-cytoplasm ratios, compact colony morphology, and clearly defined borders, consistent with established iPSC features. The appearance of colonies between days 10 and 14 post-



Figure 5: Initial competition assay results using low-density target cells. (Sensorgrams of mAb1 binding to immobilized detection antibody after pre-incubation with varying concentrations of mAb2, showing low binding signals due to insufficient antigen density).



Figure 6: High-density cell immobilization improves SPR signal. (Comparison of sensorgrams between low and high target cell immobilization levels, demonstrating enhanced mAb1 binding signals and improved assay sensitivity).

transduction aligns with previous reports, confirming the reproducibility of this non-integrating reprogramming approach [21].

Immunocytochemistry and quantitative gene expression analyses confirmed robust activation of core pluripotency markers including OCT4, SOX2, NANOG, LIN28, and REX1. The significant upregulation of these markers at both protein and transcriptional levels indicates the successful establishment of the pluripotency network in reprogrammed cells (Figure 7). These findings were supported by epigenetic analyses, which revealed hypomethylation of CpG islands in pluripotency gene promoters and enrichment of activating histone modifications (H3K4me3 and H3K27ac), while repressive marks were diminished. Together, these data confirm that somatic cell reprogramming involves a coordinated resetting of the epigenetic landscape, which is crucial for the stable acquisition of pluripotency (Figure 8).

Our study further highlights the critical role of molecular pathway orchestration during reprogramming. Activation of Wnt/β-catenin, PI3K/AKT, and MAPK pathways, along with the inhibition of TGF-β/SMAD signaling, collectively supported both the survival of intermediate-stage cells and the progression toward a pluripotent state. These observations underscore the need for precise modulation of signaling networks to enhance reprogramming efficiency and stability [22].

Single-cell transcriptomic analysis revealed significant heterogeneity among cells at intermediate stages of reprogramming, identifying a continuum from fibroblast-like cells to fully reprogrammed iPSCs. The gradual upregulation of stem cell maintenance and cell cycle genes, coupled with the downregulation of fibroblast identity markers, illustrates the stepwise molecular reprogramming trajectory [23-27]. This heterogeneity emphasizes the importance of single-cell approaches in dissecting intermediate states that may serve as critical bottlenecks for improving reprogramming efficiency.

Functional assays, including embryoid body differentiation and teratoma formation, confirmed that derived iPSCs possess the hallmark ability to generate derivatives of all three germ layers, validating their pluripotent potential. Importantly, reproducibility of the reprogramming protocol was demonstrated across biological replicates, with consistent efficiency and low variability, highlighting the robustness of the optimized method [28].



Figure 7: Refined competition assay setup using selective anti-human IgG F(ab)2 capture. (Schematic showing selective detection of human mAb1 to assess competition with mouse mAb2, illustrating principle of signal increase when competition occurs).



Figure 8: SPR sensorgrams of final cell-based competition assay. (Dose-dependent sensorgrams showing increased binding of free mAb1 to the chip in response to increasing mAb2 concentrations, confirming competition for the same epitope).

Collectively, the findings provide a comprehensive view of the interplay between transcriptional activation, epigenetic remodeling, and pathway signaling that underlies somatic cell reprogramming. The ability to monitor these events in a sequential and integrated manner offers valuable insights for improving reprogramming strategies and provides a framework for future studies aimed at enhancing iPSC generation efficiency. Moreover, the approach outlined here establishes a foundation for applying iPSC technology in disease modeling, drug discovery, and regenerative medicine, where the quality, stability, and functional competence of reprogrammed cells are critical. Study emphasizes that somatic cell reprogramming is a tightly regulated and multistage process, where successful induction of pluripotency requires not only the expression of core transcription factors but also coordinated modulation of signaling pathways and epigenetic remodeling. By providing a detailed molecular and functional roadmap, this work advances our understanding of iPSC biology and offers practical insights for optimizing reprogramming protocols for research and therapeutic applications.

CONCLUSION

Somatic cell reprogramming into iPSCs is a highly coordinated, multistage process that requires precise modulation of transcriptional networks, signaling pathways, and epigenetic states. The methodologies and insights presented here offer a valuable foundation for enhancing reprogramming efficiency and provide a practical framework for utilizing iPSC technology in disease modeling, drug discovery, and regenerative medicine, ultimately advancing the development of safe, effective, and clinically relevant pluripotent stem cell applications.

REFERENCES

1. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861–872.
2. Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917–1920.
3. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676.
4. Hochedlinger, K., & Jaenisch, R. (2006). Nuclear reprogramming and pluripotency. Nature, 441(7097), 1061–1067.
5. Polo, J. M., Anderssen, E., Walsh, R. M., Schwarz, B. A., Nefzger, C. M., Lim, S. M., et al. (2012). A molecular roadmap of reprogramming somatic cells into iPS cells. Cell, 151(7), 1617–1632.
6. Buganim, Y., Faddah, D. A., & Jaenisch, R. (2013). Mechanisms and models of somatic cell reprogramming. Nature Reviews Genetics, 14(6), 427–439.
7. Stadtfeld, M., Maherali, N., Breault, D. T., & Hochedlinger, K. (2008). Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell, 2(3), 230–240.
8. Mikkelsen, T. S., Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P., et al. (2008). Dissecting direct reprogramming through integrative genomic analysis. Nature, 454(7200), 49–55.
9. Li, R., Liang, J., Ni, S., Zhou, T., Qing, X., Li, H., et al. (2010). A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell, 7(1), 51–63.
10. Samavarchi-Tehrani, P., Golipour, A., David, L., Sung, H. K., Beyer, T. A., Datti, A., et al. (2010). Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell, 7(1), 64–77.
11. Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., et al. (2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature, 448(7151), 318–324.
12. Zhou, H., Wu, S., Joo, J. Y., Zhu, S., Han, D. W., Lin, T., et al. (2009). Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 4(5), 381–384.
13. Mali, P., Ye, Z., Hommond, H., Yu, J., Silberg, J., & Prasad, V., et al. (2008). Improved efficiency and pace of generating induced pluripotent stem cells from human fibroblasts. Stem Cells, 26(8), 1998–2005.
14. Kim, J. B., Sebastiano, V., Wu, G., Araúzo-Bravo, M. J., Sasse, P., Gentile, L., et al. (2009). Oct4-induced pluripotency in adult neural stem cells. Cell, 136(3), 411–419.
15. Loh, Y. H., Agarwal, S., Park, I. H., Urbach, A., Huo, H., Heffner, G. C., et al. (2009). Generation of induced pluripotent stem cells from human blood. Blood, 113(22), 5476–5479.
16. Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., & Yamanaka, S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science, 322(5903), 949–953.
17. Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., & Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy Series B, 85(8), 348–362.
18. Stadtfeld, M., & Hochedlinger, K. (2010). Induced pluripotency: history, mechanisms, and applications. Genes & Development, 24(20), 2239–2263.
19. Buganim, Y., Faddah, D. A., Cheng, A. W., Itskovich, E., Markoulaki, S., Ganz, K., et al. (2012). Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell, 150(6), 1209–1222.
20. Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C. J., Creyghton, M. P., et al. (2009). Direct cell reprogramming is a stochastic process amenable to acceleration. Nature, 462(7273), 595–601.

21. Rais, Y., Zviran, A., Geula, S., Gafni, O., Chomsky, E., Viukov, S., et al. (2013). Deterministic direct reprogramming of somatic cells to pluripotency. Nature, 502(7469), 65–70.

22. Kim, D., Kim, C. H., Moon, J. I., Chung, Y. G., Chang, M. Y., Han, B. S., et al. (2009). Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell, 4(6), 472–476.

23. Chen, J., Liu, H., Liu, J., Wang, Y., Zhao, Y., Ye, X., et al. (2013). H3K27 demethylation is required for somatic cell reprogramming. Nature Cell Biology, 15(6), 666–674.

24. Lister, R., Pelizzola, M., Kida, Y. S., Hawkins, R. D., Nery, J. R., Hon, G., et al. (2011). Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature, 471(7336), 68–73.

25. Mikkelsen, T. S., Ku, M., Jaffe, D. B., Issac, B., Lieberman, E., Giannoukos, G., et al. (2007). Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature, 448(7153), 553–560.

26. Hanna, J., Markoulaki, S., Schorderet, P., Carey, B. W., Beard, C., Wernig, M., et al. (2008). Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell, 133(2), 250–264.

27. Apostolou, E., & Hochedlinger, K. (2013). Chromatin dynamics during cellular reprogramming. Nature, 502(7472), 462–471.

28. Stadtfeld, M., Maherali, N., Breault, D. T., & Hochedlinger, K. (2008). Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell, 2(3), 230–240.

Citation: Olchowik B, Vorsanova F, Arroyo M (2025) Molecular Pathway Orchestration During Somatic Cell Reprogramming to Induced Pluripotent Stem Cells. Appl Cell Biol, 13(3), [57-64]